search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
SIR 2020 VIRTUAL best posters By Baljendra Kapoor, MD, FSIR Best posters of SIR 2020 VIRTUAL


On June 13–14, SIR presented SIR 2020 VIRTUAL—a novel and accessible online scientific meeting. Over 2 days, registrants attended presentations on late-breaking, noteworthy and outstanding abstracts and participated in sessions to earn SA-CME credits. The virtual meeting highlighted the science that is at the heart of the annual scientific meeting and was supported by more than 700 posters. The Annual Meeting Committee selected four submissions to recognize with the distinction of Best Poster for SIR 2020. These posters were chosen based on their merit, scoring andeducational and scientific content, including oncologic and nononcologic interventions, basic science and clinical interventional radiology. The descriptions below further explain why each poster was selected for the award.


Rapamycin-eluting polymeric stents for biomedical applications


Poster number: 437 Authors: A Mu, J Damasco, J Perez, R Rojo, S Huang, M Melancon


Neointimal hyperplasia and restenosis of treated atherosclerotic lesions is a major complication of percutaneous interventions, leading to a high cost burden for affected patients. Most of the research regarding the management of peripheral arterial disease (such as research into drug-coated balloons and stents) has been directed toward decreasing neointimal hyperplasia, with the goal of improving patency and clinical outcomes in these patients.


More research is needed regarding how to improve the patency of the treated lesions. This study explores polymeric drug-eluting platforms that may offer a solution to the problem of restenosis of treated lesions. Sustained release of antiproliferative drugs can inhibit neointimal hyperplasia while polymer degradation can allow for endothelial recovery.


This study assesses how to optimize the design and efficacy of a rapamycin- eluting polycaprolactone stent in terms of in vitro biocompatibility and drug release.


Combining neutrophil-lymphocyte ratio (NLR) with serum albumin and bilirubin (NALBI) is superior to calculated albumin/bilirubin (ALBI) grade in predicting overall survival (OS) and progression- free survival (PFS) following chemoembolization (TACE) of hepatocellular carcinoma (HCC)


Poster number: 531 Authors: J Wen, C Cable, D North, J Watchmaker, R Imani-Shikhabadi, E Hevert, D Holzwanger, J Baker, L Matsuoka, S Alexopoulos, T Borgmann, F Banovac, D Brown


There is a need to identify better predictors of response, overall survival and progression-free survival following locoregional therapy in patients with HCC. Various predictors of response and survival such as neutrophil-lymphocyte ratio and platelet lymphocyte ratio have been described in literature.


This study combines NLR with serum albumin and bilirubin predictors to identify if this combination, NLR– albumin/bilirubin (ALBI) grade (NALBI), is more useful in predicting overall survival (OS) and progression free survival among patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma.


This study shows that combining NLR with serum albumin and bilirubin (NALBI) is superior to ALBI grade in predicting OS and progression-free survival following chemoembolization of hepatocellular carcinoma.


CRISPR-based genome editing identifies metabolic dependencies of a biopsy-derived HCC cell line, enabling targeted therapy selection and response evaluation


Poster number: 693 Authors: N Perkons, O Johnson, G Pilla, E Profka, M Mercadante, D Ackerman, G Nadolski, S Hunt, T Gade


The HCC tumors plays an important role in the variable response to treatment and overall survival seen among patients with these tumors. This research highlights the use of recently introduced cutting-edge molecular biology techniques such as CRISPR-based genome editing combined with other advanced techniques such as dynamic nuclear polarization and magnetic resonance spectroscopic imaging to elucidate and quantify variations in metabolic activity, to more effectively target therapy development and patient selection, and to evaluate treatment response, eventually leading to better clinical outcomes in these patients.


These posters are available to view anytime at sirmeeting.org.


Cracking calcium with big waves: A review of intravascular lithotripsy


Poster number: 855 Authors: H Reynolds, M Patel, O Adenikinju, S C. Durscki Vianna, A Zybulewski, R Beasley, B Olivieri


The use of intravascular lithotripsy in peripheral arterial disease is new, and at present this technique is therefore not widely used particularly in atherosclerotic peripheral arterial disease. Very limited literature is available. Critical limb ischemia (CLI) is a serious, life-threatening condition that is associated with significant morbidity and mortality in patients with atherosclerotic peripheral arterial disease. Almost one-fourth of the patients, within the first year of CLI diagnosis, will die or undergo a major limb amputation. The presence of arterial calcification in patients with CLI increases mortality by 50% and is associated with a 5-fold increase in the rate of major amputation.


More and more research is needed in this area of atherosclerotic disease to improve clinical outcome in these patients. This poster describes the technique of intravascular lithotripsy and highlights its potential role as an adjunctive treatment modality for the treatment of peripheral arterial disease.


sirweb.org/irq | 19


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40